HBM Healthcare Investments

Overview
Price performance
Financials
Research
Thematics

HBMN aims to generate long-term capital gains through direct investments in emerging private and public companies in biotechnology, human medicine, diagnostics, medical technology and related areas.

Latest Insights

Investment Companies |
edison tv

09.10.24

HBM Healthcare Investments – executive interview

Investment Companies |
Review

25.05.22

HBM Healthcare Investments — Looking ahead to renewed opportunities

Investment Companies |
Review

03.06.21

HBM Healthcare Investments — A stellar year to mark 20th anniversary

Investment Companies |
Flash note

04.02.21

HBM Healthcare Investments — Top 10 holding Viela Bio to be taken out for $3bn

Visit Website

Sector

Investment Companies

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(1.0)	(12.1)	(14.5)
Relative	(6.0)	(12.4)	(9.3)
52 week high/low	€275.0/€192.2

Overview

HBM Healthcare Investments (HBMN) posted its first NAV loss in a decade for FY22 (ended 31 March), but, as shown in the chart below, its long-term performance record remains very impressive. The recent fall in the share price from a premium to a discount to NAV (10.0% at 20 May) could present an opportunity for long-term investors who, like HBMN’s management team, remain convinced of the long-term opportunities afforded by careful investment in the healthcare and biotechnology space. HBMN is unusual among its peers in offering a portfolio made up of private companies, listed equities and funds, broadly spread by geography and clinical focus, with a high distribution policy (current yield of 3.8%).